FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

Print this page SUMMIT, N.J.–(BUSINESS WIRE) July 19, 2019 — Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. Otezla, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the… Read More »

Which Health Conditions Are Most Likely to Be Misdiagnosed?

Patients depend on doctors to accurately diagnose their illnesses. But a recent study published in the journal Diagnosis has found that diagnostic errors account for nearly three fourths of all severe medical problems in three disease categories: vascular events, infections and cancers, according to a Johns Hopkins Medicine news release. For the study, researchers evaluated… Read More »